How big is Roivant Sciences Ltd.?

As of Jun 18, Roivant Sciences Ltd. has a market capitalization of 7,552.65 million and reported net sales of 76.19 million with a net profit loss of 640.67 million for the latest four quarters ending in March 2025.

Market Cap: <BR>As of Jun 18, Roivant Sciences Ltd. has a market capitalization of 7,552.65 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters ending in March 2025, Roivant Sciences Ltd. reported net sales of 76.19 million. However, the company experienced a net profit loss of 640.67 million during the same period.<BR><BR>Balance Sheet Snapshot: <BR>As of March 2025, Roivant Sciences Ltd. reported shareholder's funds of 4,687.60 million and total assets amounting to 5,436.94 million.

What does Roivant Sciences Ltd. do?

Roivant Sciences Ltd. is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $8 million and a net loss of $252 million as of March 2025. It has a market cap of approximately $7.55 billion, with key metrics indicating it is currently loss-making and does not pay dividends.

Overview: <BR>Roivant Sciences Ltd. operates in the Pharmaceuticals & Biotechnology industry and is classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -252 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 7,552.65 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -17.21% <BR>Price to Book: 1.61<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Roivant Sciences Ltd.?

Is Roivant Sciences Ltd. overvalued or undervalued?

As of February 10, 2025, Roivant Sciences Ltd. is considered overvalued with negative financial metrics despite strong stock performance, indicating a risky valuation grade compared to peers.

As of 10 February 2025, Roivant Sciences Ltd. has moved from a fair to a risky valuation grade. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.63, an EV to EBIT of -2.43, and an ROE of -17.21%. In comparison to peers, Neurocrine Biosciences, Inc. has a P/E ratio of 37.08, while Viatris, Inc. shows a P/E of 44.86, both indicating a stark contrast in valuation metrics.<BR><BR>Despite the unfavorable valuation, Roivant Sciences has demonstrated strong stock performance, with a 1Y return of 25.75% compared to the S&P 500's 17.14%, and an impressive 5Y return of 589.04% against the S&P 500's 96.61%. This performance may suggest some investor optimism, but the underlying financial ratios indicate that the stock is not justified at its current price level.

Is Roivant Sciences Ltd. technically bullish or bearish?

As of August 22, 2025, Roivant Sciences Ltd. shows a bullish technical trend supported by positive MACD, Bollinger Bands, and moving averages, despite a mildly bearish KST, with strong performance outpacing the S&P 500 over both 1-month and 3-year periods.

As of 22 August 2025, the technical trend for Roivant Sciences Ltd. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also indicate a bullish stance on both time frames. The daily moving averages are bullish as well. However, the KST shows a mildly bearish signal on the monthly, and both the weekly and monthly Dow Theory and OBV are mildly bullish. <BR><BR>The stock has demonstrated strong performance compared to the S&P 500, with a 1-month return of 27.77% versus 2.33% for the index, and a 3-year return of 364.31% compared to 70.41%. Overall, the current technical stance is bullish with strong momentum indicators supporting this view.